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RESEARCH UTILIZATION AND IMPACT

TRANSLATING EVIDENCE INTO IMPACT

ICA Foundation Supports LNG IUS Access in Low- and MiddleIncome Countries
The Population Council has developed and introduced several of the world’s most effective
and popular contraceptive methods, including the levonorgestrel-releasing intrauterine
system (LNG IUS). Through the International Contraceptive Access (ICA) Foundation, a
public-private foundation based in Finland, the Council supports LNG IUS distribution
to women in over 35 low- and middle-income countries (LMICs) in partnership with
international and local organizations. Over 150,000 LNG IUS units have been delivered
to date at no cost, laying the groundwork for method introduction in LMICs and further
expanding access to safe, long-acting, reversible contraception.

INTRODUCTION
The Population Council began developing Mirena® in
the late 1970s1 with the aim of creating a contraceptive
device combining the beneficial features of both
hormonal contraceptives and intrauterine devices.
Mirena®, approved by the Food and Drug Administration
in 2000 and added to the World Health Organization’s
Essential Medicines list in 2015, provides up to six years
of safe, effective, and continuous contraception for
women.
Mirena®, produced in Finland by Bayer, is distributed
in the private market and is available in more than
120 countries. “LNG IUS” is the version of the product
distributed in the public sector ouside the United
States. However, Mirena® and other branded longacting reversible contraceptive (LARC) products remain
prohibitively expensive2 for many users. Service delivery
and demand constraints have also hindered large-scale
public sector introductions of the method.
The Council remains committed to continuing to
improve access to the LNG IUS and other reproductive
health products serving women and men in LMICs.

In 2004, the Population Council and Bayer AG joined
forces to establish the ICA Foundation, a public-private
partnership, as a creative way of enhancing access to
this innovative product. The Foundation, through its
network of partners across multiple countries, has been
engaged in serving women’s needs for expanded longacting reversible contraceptive options. The Council
holds two ex-officio board seats on the Foundation and
three positions on the Secretariat that manages the
Foundation’s affairs.
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RESEARCH SUMMARY
The Council’s development of the LNG IUS/Mirena®
with Bayer Oy (formerly Leiras Oy) sought to
improve available intrauterine devices with the aim of
decreasing menstrual bleeding and preventing anemia
with the addition of a progestin (levonorgestrel, hence
the generic name). The commercially marketed
Mirena® was approved by the FDA for contraception in
2000 and later for the treatment of heavy menstrual
bleeding. The LNG IUS is available on a not-for-profit
basis through donations by the ICA Foundation to
service delivery organizations working in low-resource
settings.
The LNG IUS has numerous benefits:3 up to six
years of protection, a pregnancy rate of less than 1
percent in the first year of use, a strong safety record
comparable to sterilization, rapid return to fertility
after removal, the ability to lighten menstrual bleeding
and cramping, and the potential reduction in irondeficiency anemia. Clinical data is available for over
13,000 women-years of product use, demonstrating
high efficacy and acceptance.

RESEARCH USE AND IMPACT
The Council plays a unique role by employing
a “bench to bedside” approach,4 investing in
contraceptive development from early laboratory
research to product introduction. To expand
contraceptive options and provide access to the LNG
IUS across varied settings, the Population Council and
Bayer AG, through the ICA Foundation, have provided
the unbranded LNG IUS on a not-for-profit basis for
over 15 years.
To date, the ICA Foundation has donated over
150,000 LNG IUS devices5 to organizations in 37
LMICs, helping to prevent thousands of unintended
pregnancies, unsafe abortions, and maternal
deaths.6 These donations support the work of
governments and local not-for-profit organizations,
hospitals, and global partners that share the
Council’s commitment to improving access to quality
family planning services and expanding modern
contraceptive options.
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Across multiple contexts, ICA Foundation
donations have responded to growing demand
for modern contraception, expanded access to
LARCs, and laid the groundwork for LNG IUS
introduction in multiple LMICs. In several countries,
such as Kenya, Nigeria, and Zambia, donated LNG
IUS units have supported demonstration projects
that provided a foundation for broader access to the
method, institutionalization within national health
systems, opportunities for regional replication and
encouraging new manufacturing options.
The ICA Foundation has responded to growing
demand for LARCs by supporting efforts to expand
access to the LNG IUS through the public sector
in multiple countries. In Kenya, recent LNG IUS
donations contributed to a Jhpiego-coordinated
initiative7 to build capacity for increasing access to
modern contraception, including LARCs, through
public-sector facilities in Kisumu and Migori
counties. In partnership with the Ministry of Health,
the LNG IUS was added to the modern contraceptive
options offered at select high-volume facilities.
Through these collaborative efforts, the LNG IUS
is now included in Kenya’s national family planning
training curriculum and health information systems.
In addition, efforts are underway to transition
management of commodity donations from Jhpiego
to the Government of Kenya.
Modest donations of LNG IUS product have been
catalytic in setting the stage for sustained efforts to
increase access to the method within existing health
systems by energizing service delivery organizations,
harnessing the reach of professional associations,
and creating linkages between public and private
stakeholders. In Nigeria, LNG IUS donations have
supported the efforts of Rotary and several local
partners promoting provider skills-building activities;
community outreach involving men and religious
leaders; and increased availability of modern
contraceptives, including LARCs, across multiple
states. The ICA Foundation, in collaboration with
these partners and others, has also contributed
to recent efforts by Nigeria’s Federal Ministry of
Health to sustain and expand access to hormonal
IUS through a national plan for coordinated and
phased introduction within the country’s health
system.

LOOKING FORWARD

KEY IMPACTS

LNG IUS DONATIONS IN KENYA SUPPORTED
LARC CAPACITY-BUILDING EFFORTS
IN PUBLIC-SECTOR FACILITIES

THE ICA FOUNDATION, WITH PARTNERS IN NIGERIA,
CONTRIBUTED TO DEVELOPMENT OF A NATIONAL
PLAN FOR HORMONAL IUS INTRODUCTION

The ICA Foundation will continue to support
increased LNG IUS availability in LMICs through its
donation program. Beyond sustained country-level
donations, the Foundation also continues to shape
global markets, demonstrating the demand for longacting methods, fostering competition, ensuring
a more reliable and greater volume of supply, and
stimulating more favorable pricing. In addition, USAID
and UNFPA are in the process of adding the hormonal
IUS to their procurement catalogs so that interested
international buyers can procure the product.

For more information, please visit the
ICA Foundation.
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Kenya Learning Brief: Incorporating the Hormonal Intrauterine System into the
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The Population Council collaborates with program implementers, policymakers, researchers, and funding partners to advance
evidence-based solutions to critical health and development challenges. The Council’s research impact briefs feature recent
highlights of our ongoing work to ensure evidence is translated into meaningful actions at community, national, regional, and
global levels to improve lives around the world.
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